Amarin (NASDAQ:AMRN – Get Free Report) posted its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.06), Zacks reports. Amarin had a negative net margin of 16.33% and a negative return on equity of 7.22%.
Amarin Stock Performance
Shares of NASDAQ:AMRN opened at $0.43 on Wednesday. Amarin has a 52-week low of $0.40 and a 52-week high of $1.11. The company has a market cap of $177.41 million, a P/E ratio of -4.96 and a beta of 1.82. The stock’s 50-day moving average is $0.56 and its 200-day moving average is $0.55.
Analyst Ratings Changes
Separately, StockNews.com raised Amarin from a “sell” rating to a “hold” rating in a research note on Friday, March 7th.
About Amarin
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
See Also
- Five stocks we like better than Amarin
- How to invest in marijuana stocks in 7 steps
- Why Energy Transfer Belongs on Your Watchlist
- Which Wall Street Analysts are the Most Accurate?
- Why Wayfair Stock May Be a Hidden Gem for Value Investors
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- 3 Investments to Consider as China’s Market Heats Up
Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.
